Bolt Biotherapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Bolt Biotherapeutics, Inc. (BOLT) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 8.83 thousand shares for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-29.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2023-03-29
- Bolt Biotherapeutics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2021-03-31 was 36.09K shares, a 79.06% decline year-over-year.
- Bolt Biotherapeutics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2020-09-30 was 162.92K shares.
- Bolt Biotherapeutics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2020-06-30 was 172.02K shares.
- Bolt Biotherapeutics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2020-03-31 was 172.31K shares.
- Bolt Biotherapeutics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2021 was 8.83K shares, a 94.02% decline from fiscal 2020.
- Bolt Biotherapeutics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2020 was 147.55K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|
| 2021-12-31 | 8.83K shares 10-K · filed 2023-03-29 | |||
| 2021-09-30 | 11.80K shares 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 17.80K shares 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | 36.09K shares 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | 147.55K shares 10-K · filed 2022-03-30 | |||
| 2020-09-30 | 162.92K shares 10-Q · filed 2021-11-09 | 168.91K shares 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | 172.02K shares 10-Q · filed 2021-08-12 | 172.02K shares 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | 172.31K shares 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |